XNAS
NVNO
Market cap181kUSD
Jul 09, Last price
11.00USD
1D
-1.08%
1Q
-0.45%
IPO
-99.75%
Name
enVVeno Medical Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Irvine, California, enVVeno Medical Corporation operates as a clinical-stage medical technology company. Its core mission revolves around pioneering advanced bioprosthetic tissue solutions aimed at elevating the standard of care for patients suffering from venous diseases. The company's flagship innovation is the VenoValve, a surgical implant engineered to address Chronic Venous Insufficiency (CVI). This device is surgically placed within the femoral vein, where it acts as a unidirectional valve, effectively re-establishing healthy blood flow in the leg. Complementing this, enVVeno is also developing enVVe, a non-invasive, transcatheter-delivered venous valve replacement, also intended for CVI treatment. Founded in 1999, the company underwent a name change in October 2021, transitioning from its former identity as Hancock Jaffe Laboratories, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||